Updates
Our CKD Screening Prioritizer is a registered medical device.
Our Chronic Kidney Disease Screening Prioritizer (CSP) has
received a UKCA marking and regulatory approval meaning...
2022: A year in Review
2022 was a year full of innovation, resilience, and creativity
Gendius was formed with a mission to help...
Gendius presents at American Society of Nephrology Conference
Diabetes technology innovator Gendius has presented research on its new data-driven tool to identify type-2 diabetes...
Research shows Gendius’ models can identify high risk patients
Newly published research shows that Gendius’ models can identify which people with diabetes are at high risk of...
Gendius presents at European Association for the Study of Diabetes (EASD) conference
Gendius presents validation of Chronic Kidney Disease pre-screening models at European Association for the Study of...
Gendius technology for diabetes risk prediction launched in the GCC
Gendius technology for diabetes risk prediction launched in the GCC through new AstraZeneca patient support app,...
Gendius initiates GP Data Study
Gendius initiates GP data study to develop enhanced risk prediction tools for diabetes
UK medtech start-up Gendius...
